- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07137338
- Ursprunglig rättegång
En fas 1 AAV-genterapi-studie utvärderar säkerhet och preliminär effektivitet av RP-A701 hos personer med BAG3 dilaterad kardiomyopati
A Phase 1 Dose Escalation Trial Evaluating an Intravenously Administered Recombinant Adeno-associated Virus Serotype rh.74 (AAVrh.74) Vector Containing the Human BCL2-associated Athanogene 3 (BAG3) Gene Coding Sequence (RP-A701) in Subjects With Dilated Cardiomyopathy Arising From Pathogenic BAG3 Variants (BAG3-DCM)
This is a Phase 1, open-label, dose-escalation trial to characterize the safety, tolerability, and preliminary efficacy of RP-A701 following a single IV administration in high-risk adult patients with BAG3-DCM.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Clinical Information
- Telefonnummer: 646-627-0033
- E-post: clinicaltrials@rocketpharma.com
Studieorter
-
-
California
-
San Diego, California, Förenta staterna, 92037
- Rekrytering
- University of California, San Diego
-
Huvudutredare:
- Barry Greenberg, MD
-
Kontakt:
- Clinical Research Coordinator
- Telefonnummer: 858-822-1722
- E-post: emoyacespedes@health.ucsd.edu
-
-
Minnesota
-
Rochester, Minnesota, Förenta staterna, 55905
- Rekrytering
- Mayo Clinic
-
Huvudutredare:
- John Giudicessi, MD, PhD
-
Kontakt:
- Clinical Research Coordinator
- Telefonnummer: 507-538-1500
- E-post: slade.sierra@mayo.edu
-
-
South Carolina
-
Charleston, South Carolina, Förenta staterna, 29425
- Rekrytering
- Medical University of South Carolina
-
Huvudutredare:
- Daniel Judge, MD
-
Kontakt:
- Clinical Res
- Telefonnummer: 843-792-2300
- E-post: andrewcl@musc.edu
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
Subjects are eligible for inclusion into the study only if all the following criteria apply:
-
Male or female between 18 and 65 years of age at the time of signing the informed consent
-
Capable of and willing to provide signed informed consent
-
Clinical diagnosis of DCM defined as and requiring each of the following:
- Mild to moderate systolic dysfunction (LVEF ≥ 25% and ≤ 45%) by echocardiography or CMR performed within 3 months of enrollment.
- Absence of severe coronary artery disease (>70% stenosis) or active myocardial ischemia as the etiology of LV systolic dysfunction
- Absence of uncontrolled hypertension, significant cardiac valve disease (i.e., greater than moderate in severity), infiltrative disorder, or systemic disease known to cause cardiomyopathy.
-
Documentation of a pathogenic or likely pathogenic variant in BAG3
-
History of ICD implantation ≥ 3 months prior to enrollment
-
NYHA Class II or III HF symptoms with stable HF therapeutic guideline-directed medical regimen for 30 days prior to enrollment
Exclusion Criteria:
- CV disease that may be related to a genetic etiology other than a BAG3 pathogenic or likely pathogenic variant.
- Previous participation in a study of gene transfer or gene editing.
- I.V. inotropic, vasodilator, or diuretic therapy ≤ 30 days prior to enrollment.
- History of intracardiac thrombosis or arterial thromboembolic events
- Severe RV dysfunction assessed by echocardiogram or CMR ≤ 12 months prior to screening
- LVEF < 25% by echocardiogram or CMR at ≤ 3 months prior to screening
- NYHA Class I or IV HF
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Single ascending dose of RP-A701 in up to 2 consecutive cohorts
Participants will receive a single intravenous dose of RP-A701 on Day 0 and will be followed for up to two years |
One-time treatment with a single ascending dose |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of Treatment-emergent Adverse Events (TEAE)
Tidsram: Baseline up to End of Study (up to 24 months post-infusion)
|
Number of participants with Adverse Events following a single IV dose of RP-A701 |
Baseline up to End of Study (up to 24 months post-infusion)
|
|
Incidence of Treatment-emergent Serious Adverse Events (SAE).
Tidsram: Baseline up to End of Study (up to 24 months post-infusion)
|
Number of participants with Serious Adverse Events (SAE) following a single IV dose of RP-A701 |
Baseline up to End of Study (up to 24 months post-infusion)
|
|
Incidence of Dose Limiting Toxicities (DLT).
Tidsram: Baseline up to End of Study (up to 24 months post-infusion)
|
Number of participants with Dose Limiting Toxicities (DLT) following a single IV dose of RP-A701 |
Baseline up to End of Study (up to 24 months post-infusion)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
To assess the impact of RP-A701 on features of cardiovascular function.
Tidsram: Baseline up to End of Study (up to 24 months post-infusion)
|
Change in measures of LV systolic function, including LV ejection fraction (LVEF), LV global longitudinal strain. |
Baseline up to End of Study (up to 24 months post-infusion)
|
|
To assess the impact of RP-A701 on features of cardiovascular function.
Tidsram: Baseline up to End of Study (up to 24 months post-infusion)
|
Change in peak oxygen consumption (VO2) or ventilatory efficiency (VE/VCO2 slope) by cardiopulmonary exercise test (CPET) |
Baseline up to End of Study (up to 24 months post-infusion)
|
|
To assess the impact of RP-A701 on features of cardiovascular function.
Tidsram: Baseline up to End of Study (up to 24 months post-infusion)
|
Change in 6-minute walk distance. |
Baseline up to End of Study (up to 24 months post-infusion)
|
|
To assess the extent of RP-A701 transduction and protein expression.
Tidsram: Baseline up to End of Study (up to 24 months post-infusion)
|
Change in BAG3 myocardial protein expression |
Baseline up to End of Study (up to 24 months post-infusion)
|
|
To assess the impact of RP-A701 on features of heart failure (HF).
Tidsram: Baseline up to End of Study (up to 24 months post-infusion)
|
Change in symptoms of HF assessed by New York Heart Association (NYHA) class. |
Baseline up to End of Study (up to 24 months post-infusion)
|
|
To assess the impact of RP-A701 on quality of life.
Tidsram: Baseline up to End of Study (up to 24 months post-infusion)
|
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ-12) Overall Summary Score. |
Baseline up to End of Study (up to 24 months post-infusion)
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- RP-A701-0125
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .